指南与共识消化、代谢与肾脏急症重症综合管理与镇静镇痛

共识文件与随机试验在重症肾脏病学中的影响力比较

Impact of Consensus Papers versus Randomized Trials in Critical Care Nephrology.
指南 / 共识 · Blood Purif · 2020-04-08
一句话结论在重症肾脏病学领域,ADQI共识报告与同年同主题随机试验的引用次数相似,尽管共识报告发表的期刊影响因子更低。

该研究比较了2002至2017年急性疾病质量倡议(ADQI)发布的17篇共识报告与同年同主题17项随机试验的发表影响力。共识报告与随机试验的每篇引用次数中位数相似(132次 vs 159次,p无显著差异),两组均有10篇被引用超过100次。共识报告发表期刊的影响因子低于随机试验(5.4 vs 25.4,p<0.01)。每引用成本中位数ADQI报告为606.01美元,随机试验为1,182.59美元(p=0.09)。

要点

  • ADQI共识报告与同年同主题随机试验的每篇引用次数中位数相似(132次 vs 159次,p无显著差异)。
  • ADQI报告与随机试验分别有10篇(58.8%)被引用超过100次。
  • ADQI报告发表期刊的影响因子低于随机试验(5.4 vs 25.4,p<0.01)。
  • 每引用成本中位数ADQI报告为606.01美元,随机试验为1,182.59美元(p=0.09)。

研究设计与关键结果

  • 研究类型为文献计量学比较分析,匹配2002至2017年17篇ADQI共识报告与同年同主题17项随机试验。
  • 主要终点每篇引用次数中位数:ADQI报告132次(四分位距54-228)vs 随机试验159次(四分位距60-340),p无显著差异。
  • 关键次要终点:ADQI报告10篇(58.8%)与随机试验10篇被引用超过100次。
  • ADQI报告发表期刊影响因子低于随机试验(5.4±4.6 vs 25.4±27.1,p<0.01)。
  • 每引用成本中位数(2017年美元):ADQI报告606.01美元 vs 随机试验1,182.59美元,p=0.09。

证据类型、等级与局限

  • 证据类型:文献计量学比较分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「适用人群与场景」「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Reports of consensus conferences are usually valued less than reports of clinical trials even when rigorous methodology is used. However, limited data are available comparing the impact of these 2 methods of shaping clinical practice.

OBJECTIVE: Compare the publication impact of consensus conferences and clinical trials.

METHODS: Consensus publications from the Acute Disease Quality Initiative (ADQI) from 2002 through 2017 were identified and classified by subject matter. Randomized trials were identified in the same publication year and subject in journals, starting with the highest impact factor. Both publication types were matched, and total citations were determined for each using Google Scholar. A secondary analysis compared total costs for each publication type.

RESULTS AND CONCLUSIONS: Seventeen ADQI consensus conference reports and 17 randomized trials were identified. ADQI reports received a similar number of citations per paper (median, interquartile range) compared to randomized trials (132, 54-228; vs. 159, 60-340, p = ns). Similarly, 10 (58.8%) ADQI reports and 10 randomized trials were cited >100 times. On average, ADQI reports appeared in journals with lower impact factors compared to clinical trials (5.4 ± 4.6 vs. 25.4 ± 27.1; p < 0.01). The median cost per citation (USD 2017) for ADQI reports was USD 606.01 compared to almost twice this figure, USD 1,182.59, for clinical trials on the same topics (p = 0.09). Despite being published in lower impact factor journals, consensus reports on topics in critical care nephrology, received similar citations to randomized controlled trials published the same year.

来源:Blood Purif,查看原文。版权归原作者所有。

参考来源

  1. Kellum JA. Impact of Consensus Papers versus Randomized Trials in Critical Care Nephrology. Blood Purif. 2020. PMID: 32268336. doi:10.1159/000507422

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。